Your browser doesn't support javascript.
loading
Diagnosis and Treatment Patterns in Celiac Disease.
Cichewicz, Allie B; Mearns, Elizabeth S; Taylor, Aliki; Boulanger, Talia; Gerber, Michele; Leffler, Daniel A; Drahos, Jennifer; Sanders, David S; Thomas Craig, Kelly J; Lebwohl, Benjamin.
Afiliação
  • Cichewicz AB; IBM Watson Health, 75 Binney Street, Cambridge, MA, 02142, USA.
  • Mearns ES; IBM Watson Health, 75 Binney Street, Cambridge, MA, 02142, USA. elizabethmearns@gmail.com.
  • Taylor A; Takeda Development Centre Europe, 61 Aldwych, London, WC2B 4AE, UK.
  • Boulanger T; IBM Watson Health, 75 Binney Street, Cambridge, MA, 02142, USA.
  • Gerber M; Takeda Pharmaceuticals International Co, 35 Landsdowne Street, Cambridge, MA, 02139, USA.
  • Leffler DA; Takeda Pharmaceuticals International Co, 35 Landsdowne Street, Cambridge, MA, 02139, USA.
  • Drahos J; Takeda Pharmaceuticals International Co, 35 Landsdowne Street, Cambridge, MA, 02139, USA.
  • Sanders DS; Royal Hallamshire Hospital and University of Sheffield, Glossop Road, Sheffield, S10 2FJ, UK.
  • Thomas Craig KJ; IBM Watson Health, 75 Binney Street, Cambridge, MA, 02142, USA.
  • Lebwohl B; Department of Medicine, Celiac Disease Centre, Columbia University Medical Center, 180 Fort Washington Avenue, Suite 936, New York, NY, 10032, USA.
Dig Dis Sci ; 64(8): 2095-2106, 2019 08.
Article em En | MEDLINE | ID: mdl-30820708
Celiac disease (CD) is an immune-mediated gastrointestinal (GI) disorder driven by innate and adaptive immune responses to gluten. Presentation of CD has changed over time, with non-GI symptoms, such as anemia and osteoporosis, presenting more commonly. With improved screening and diagnostic methods, the reported prevalence of CD has increased globally, and there is considerable global variation in diagnostic and treatment practices. The objective of this study was to describe the current state of CD diagnosis and treatment patterns. A targeted review of literature from MEDLINE, Embase, the Cochrane Library, and screening of relevant conference abstracts was performed. The generally recommended diagnostic approach is GI endoscopy with small bowel biopsy; however, in selected patients, biopsy may be avoided and diagnosis based on positive serology and clinical symptoms. Diagnosis often is delayed; the average diagnostic delay after symptom onset is highly variable and can last up to 12 years. Barriers to accurate and timely diagnosis include atypical presentation, lack of physician awareness about current diagnostic criteria, misdiagnosis, and limited access to specialists. Currently, strict adherence to a gluten-free diet (GFD) is the only recommended treatment, which is not successful in all patients. Only one-third of patients are monitored regularly following diagnosis. Unmet needs for CD include improvements in the accuracy and timeliness of diagnosis, and the development of treatments for both refractory CD and GFD nonresponsive CD. Further research should investigate the impact of education about gluten-free eating and the availability of gluten-free foods support adherence and improve outcomes in patients with CD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Celíaca / Dieta Livre de Glúten Tipo de estudo: Diagnostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Celíaca / Dieta Livre de Glúten Tipo de estudo: Diagnostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article